[1]
|
Candido, J. and Hagemann, T. (2013) Cancer-Related Inflammation. Journal of Clinical Immunology, 33, 79-84. https://doi.org/10.1007/s10875-012-9847-0
|
[2]
|
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., et al. (1999) Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo. Journal of Experimental Medicine, 190, 617-628. https://doi.org/10.1084/jem.190.5.617
|
[3]
|
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. and Coffman, R.L. (1986) Two Types of Murine Helper T Cell Clone. I. Definition According to Profiles of Lymphokine Activities and Secreted Proteins. Journal of Immunology, 136, 2348-2357.
|
[4]
|
Liston, A. and Gray, D.H. (2014) Homeostatic Control of Regulatory T Cell Diversity. Nature Reviews Immunology, 14, 154-165. https://doi.org/10.1038/nri3605
|
[5]
|
Sakaguchi, S., Miyara, M., Costantino, C.M. and Hafler, D.A. (2010) FOXP3+ Regulatory T Cells in the Human Immune System. Nature Reviews Immunology, 10, 490-500. https://doi.org/10.1038/nri2785
|
[6]
|
Dushyanthen, S., et al. (2015) Relevance of Tumor-Infiltrating Lymphocytes in Breast Cancer. BMC Medicine, 13, 202. https://doi.org/10.1186/s12916-015-0431-3
|
[7]
|
Kang, B.W., et al. (2016) Prognostic Value of Tumor-Infiltrating Lymphocytes in Epstein-Barr Virus-Associated Gastric Cancer. Annals of Oncology, 27, 494-501.
https://doi.org/10.1093/annonc/mdv610
|
[8]
|
Schalper, K.A., et al. (2015) Objective Measurement and Clinical signiFicance of TILs in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 107, dju435. https://doi.org/10.1093/jnci/dju435
|
[9]
|
Santoiemma, P.P. and Powell, D.J. (2015) Tumor Infiltrating Lymphocytes in Ovarian Cancer. Cancer Biology & Therapy, 16, 807-820.
https://doi.org/10.1080/15384047.2015.1040960
|
[10]
|
Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. and White, D.E. (1994) Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2. Journal of the National Cancer Institute, 86, 1159-1166. https://doi.org/10.1093/jnci/86.15.1159
|
[11]
|
Galon, J., et al. (2006) Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome. Science, 313, 1960-1964.
https://doi.org/10.1126/science.1129139
|
[12]
|
Leffers, N., Gooden, M.J., de Jong, R.A., Hoogeboom, B.N., ten Hoor, K.A., Hollema, H., et al. (2009) Prognostic Significance of Tumor-Infiltrating T-Lymphocytes in Primary and Metastatic Lesions of Advanced Stage Ovarian Cancer. Cancer Immunology, Immunotherapy, 58, 449-459.
https://doi.org/10.1007/s00262-008-0583-5
|
[13]
|
Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. (2005) Intraepithelial CD8 Tumor-Infiltrating Lymphocytes and a High CD8/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 18538-18543.
https://doi.org/10.1073/pnas.0509182102
|
[14]
|
Zhang, Y.L., Li, J., Mo, H.Y., Qiu, F., Zheng, L.M., Qian, C.N., et al. (2010) Different Subsets of Tumor Infiltrating Lymphocytes Correlate with NPC Progression in Different Ways. Molecular Cancer, 9, Article No. 4.
https://doi.org/10.1186/1476-4598-9-4
|
[15]
|
Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004) Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival. Nature Medicine, 10, 942-949.
https://doi.org/10.1038/nm1093
|
[16]
|
Barnett, B., Kryczek, I., Cheng, P., Zou, W. and Curiel, T.J. (2005) Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. American Journal of Reproductive Immunology, 54, 369-377.
https://doi.org/10.1111/j.1600-0897.2005.00330.x
|
[17]
|
Morse, M.A., Hobeika, A.C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H.K., et al. (2008) Depletion of Human Regulatory T Cells Specifically Enhances Antigen-Specific Immune Responses to Cancer Vaccines. Blood, 112, 610-618.
https://doi.org/10.1182/blood-2008-01-135319
|
[18]
|
Powell Jr., D.J., Attia, P., Ghetie, V., Schindler, J., Vitetta, E.S. and Rosenberg, S.A. (2008) Partial Reduction of Human FOXP3 CD4 T Cells in Vivo after CD25-Directed Recombinant Immunotoxin Administration. Journal of Immunotherapy, 31, 189-198. https://doi.org/10.1097/CJI.0b013e31815dc0e8
|
[19]
|
Bates, G.J., Fox, S.B., Han, C., Leek, R.D., Garcia, J.F., Harris, A.L., et al. (2006) Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. Journal of Clinical Oncology, 24, 5373-5380. https://doi.org/10.1200/JCO.2006.05.9584
|
[20]
|
Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G.A., Fan, Y., et al. (2011) CD8(+) Cytotoxic T Cell and FOXP3+ Regulatory T Cell Infiltration in Relation to Breast Cancer Survival and Molecular Subtypes. Breast Cancer Research and Treatment, 130, 645-655. https://doi.org/10.1007/s10549-011-1647-3
|
[21]
|
Andre, F., Dieci, M.V., Dubsky, P., Sotiriou, C., Curigliano, G., Denkert, C., et al. (2013) Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer. Clinical Cancer Research, 19, 28-33.
https://doi.org/10.1158/1078-0432.CCR-11-2701
|
[22]
|
Takenaka, M., Seki, N., Toh, U., Hattori, S., Kawahara, A., Yamaguchi, T., Koura, K., Takahashi, R., Otsuka, H., Takahashi, H., et al. (2013) FOXP3 Expression in Tumor Cells and Tumor-Infiltrating Lymphocytes Is Associated with Breast Cancer Prognosis. Molecular and Clinical Oncology, 1, 625-632.
https://doi.org/10.3892/mco.2013.107
|
[23]
|
Shang, B., Liu, Y., Jiang, S.J. and Liu, Y. (2015) Prognostic Value of Tumor-Infiltrating FoxP3+ Regulatory T Cells in Cancers: A Systematic Review and Meta-Analysis. Scientific Reports, 5, Article No. 15179. https://doi.org/10.1038/srep15179
|
[24]
|
de Ruiter, E.J., Ooft, M.L., Devriese, L.A. and Willems, S.M. (2017) The Prognostic Role of Tumor Infiltrating T-Lymphocytes in Squamous Cell Carcinoma of the Head and Neck: A Systematic Review and Meta-Analysis. Oncoimmunology, 6, e1356148. https://doi.org/10.1080/2162402X.2017.1356148
|
[25]
|
Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A, Dreno B. (2011) Prognostic Value of Tumor-Infiltrating Foxp3+ T-Cell Subpopulations in Metastatic Melanoma. Experimental Dermatology, 20, 430-434.
https://doi.org/10.1111/j.1600-0625.2011.01260.x
|
[26]
|
Lagouros, E., Salomao, D., Thorland, E., Hodge, D.O., Vile, R. and Pulido, J.S. (2009) Infiltrative T Regulatory Cells in Enucleated Uveal Melanomas. Transactions of the American Ophthalmological Society, 107, 223-228.
|
[27]
|
Mougiakakos, D., Johansson, C.C., Trocme, E., All-Ericsson, C., Economou, M.A., Larsson, O., Seregard, S. and Kiessling, R. (2010) Intratumoral Forkhead Box P3-Positive Regulatory T Cells Predict Poor Survival in Cyclooxygenase-2-Positive Uveal Melanoma. Cancer, 116, 2224-2233. https://doi.org/10.1002/cncr.24999
|
[28]
|
Lee, G.R. (2017) Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. Mediators of Inflammation, 2017, Article ID: 5458178.
https://doi.org/10.1155/2017/5458178
|
[29]
|
Assudani, D.P., Horton, R.B.V., Mathieu, M.G., McArdle, S.E.B. and Rees, R.C. (2007) The Role of CD4+ T Cell Help in Cancer Immunity and the Formulation of Novel Cancer Vaccines. Cancer Immunology, Immunotherapy, 56, 70-80.
https://doi.org/10.1007/s00262-006-0154-6
|
[30]
|
Zou, W. (2006) Regulatory T Cells, Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 6, 295-307. https://doi.org/10.1038/nri1806
|
[31]
|
Ascierto, P.A. and Marincola, F.M. (2014) What Have We Learned from Cancer Immunotherapy in the Last 3 Years? Journal of Translational Medicine, 12, Article No. 141. https://doi.org/10.1186/1479-5876-12-141
|
[32]
|
Murala, S., Alli, V., Kreisel, D., Gelman, A.E. and Krupnick, A.S. (2010) Current Status of Immunotherapy for the Treatment of Lung Cancer. Journal of Thoracic Disease, 2, 237-244.
|
[33]
|
Wright, S.E. (2012) Immunotherapy of Breast Cancer. Expert Opinion on Biological Therapy, 12, 479-490. https://doi.org/10.1517/14712598.2012.665445
|
[34]
|
Shore, N.D. (2015) Advances in the Understanding of Cancer Immunotherapy. BJU International, 116, 321-329. https://doi.org/10.1111/bju.12692
|
[35]
|
Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., et al. (2011) Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 17, 4550-4557. https://doi.org/10.1158/1078-0432.CCR-11-0116
|
[36]
|
Topalian, S.L., et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. The New England Journal of Medicine, 366, 2443-2454.
https://doi.org/10.1056/NEJMoa1200690
|
[37]
|
Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. https://doi.org/10.1056/NEJMoa1003466
|
[38]
|
Hamid, O., et al. (2013) Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. The New England Journal of Medicine, 369, 134-144.
https://doi.org/10.1056/NEJMoa1305133
|
[39]
|
Postow, M.A., et al. (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. The New England Journal of Medicine, 372, 2006-2017.
https://doi.org/10.1056/NEJMoa1414428
|
[40]
|
Wolchok, J.D., et al. (2013) Nivolumab plus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 369, 122-133.
https://doi.org/10.1056/NEJMoa1302369
|
[41]
|
Le, D.T., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520.
https://doi.org/10.1056/NEJMoa1500596
|
[42]
|
Lu, Y.-C., et al. (2014) Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research, 20, 3401-3410. https://doi.org/10.1158/1078-0432.CCR-14-0433
|
[43]
|
Lu, Y.-C., et al. (2013) Mutated PPP1R3B Is Recognized by T Cells Used to Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. The Journal of Immunology, 190, 6034-6042. https://doi.org/10.4049/jimmunol.1202830
|
[44]
|
Abd-El-Rheem, M.S.A. Moist Heat as Immune Therapy for Non Curable Diseases.
https://www.researchgate.net/publication/237673914
|
[45]
|
Robbins, P.F., et al. (2013) Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-Reactive T Cells. Nature Medicine, 19, 747-752. https://doi.org/10.1038/nm.3161
|
[46]
|
van Rooij, N., et al. (2013) Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. Journal of Clinical Oncology, 31, e439-e442. https://doi.org/10.1200/JCO.2012.47.7521
|
[47]
|
Snyder, A., et al. (2014) Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. The New England Journal of Medicine, 371, 2189-2199.
https://doi.org/10.1056/NEJMoa1406498
|
[48]
|
Rizvi, N.A., et al. (2015) Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128.
https://doi.org/10.1126/science.aaa1348
|
[49]
|
Lawrence, M.S., et al. (2013) Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes. Nature, 499, 214-218.
https://doi.org/10.1038/nature12213
|
[50]
|
Vogelstein, B., et al. (2013) Cancer Genome Landscapes. Science, 339, 1546-1558.
https://doi.org/10.1126/science.1235122
|
[51]
|
Tran, E., Robbins, P.F. and Rosenberg, S.A. (2017) “Final Common Pathway” of Human Cancer Immunotherapy: Targeting Random Somatic Mutations. Nature Immunology, 18, 255-262. https://doi.org/10.1038/ni.3682
|
[52]
|
McGranahan, N., Furness, A.J.S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., et al. (2016) Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade. Science, 351, 1463-1469.
https://doi.org/10.1126/science.aaf1490
|
[53]
|
Jamal-Hanjani, M., Wilson, G.A., McGranahan, N., Birkbak, N.J., Watkins, T.B.K., Veeriah, S., et al. (2017) Tracking the Evolution of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2109-2121.
https://doi.org/10.1056/NEJMoa1616288
|
[54]
|
Criscitiello, C. and Curigliano, G. (2013) Immunotherapeutics for Breast Cancer. Current Opinion in Oncology, 25, 602-608.
https://doi.org/10.1097/CCO.0000000000000020
|
[55]
|
Ghochikyan, A., Pichugin, A., Bagaev, A., et al. (2014) Targeting TLR-4 with a Novel Pharmaceutical Grade Plant Derived Agonist, Immunomax®, as a Therapeutic Strategy for metastatic breast cancer. Journal of Translational Medicine, 12, Article No. 322. https://doi.org/10.1186/s12967-014-0322-y
|
[56]
|
Allen, P.B. and Gordon, L.I. (2016) PD-1 Blockade in Hodgkin’s Lymphoma: Learning New Tricks from an Old Teacher. Expert Review of Hematology, 9, 939-949. https://doi.org/10.1080/17474086.2016.1235970
|
[57]
|
Beckermann, K.E., Johnson, D.B. and Sosman, J.A. (2017) PD-1/PD-L1 Blockade in Renal Cell Cancer. Expert Review of Clinical Immunology, 13, 77-84.
https://doi.org/10.1080/1744666X.2016.1214575
|
[58]
|
Beckermann, K.E., Jolly, P.C., Kim, J.Y., Bordeaux, J., Puzanov, I., Rathmell, W.K. and Johnson, D.B. (2017) Clinical and Immunologic Correlates of Response to PD-1 Blockade in a Patient with Metastatic Renal Medullary Carcinoma. Journal for ImmunoTherapy of Cancer, 5, 1.
|
[59]
|
Garon, E.B. (2015) Current Perspective Sin Immunotherapy for Non-Small Cell Lung Cancer. Seminars in Oncology, 42, S11-S18.
https://doi.org/10.1053/j.seminoncol.2015.09.019
|
[60]
|
Garon, E.B. (2015) Selecting Patients for Immune Checkpoint Inhibition in Lung Cancer. Clinical Advances in Hematology & Oncology, 13, 490-492.
|
[61]
|
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 372, 2521-2532. https://doi.org/10.1056/NEJMoa1503093
|
[62]
|
Sonpavde, G. (2017) PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma. The New England Journal of Medicine, 376, 1073-1074.
https://doi.org/10.1056/NEJMe1701182
|
[63]
|
Tewari, K.S. and Monk, B.J. (2014) New Strategies in Cervical Cancer: From Angiogenesis Blockade to Immunotherapy. Clinical Cancer Research, 20, 5349-5358.
https://doi.org/10.1158/1078-0432.CCR-14-1099
|
[64]
|
Gaillard, S.L., Secord, A.A. and Monk, B. (2016) The Role of Immune Checkpoint Inhibition in the Treatment of Ovarian Cancer. Gynecologic Oncology Research and Practice, 24, Article No. 11. https://doi.org/10.1186/s40661-016-0033-6
|
[65]
|
Khanna, S., Thomas, A., Abate-Daga, D., Zhang, J., Morrow, B., Steinberg, S.M., Orlandi, A., Ferroni, P., Schlom, J., Guadagni, F., et al. (2016) Malignant Mesothelioma Effusions are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 11, 1993-2005.
|
[66]
|
Lordick, F., Shitara, K. and Janjigian, Y.Y. (2017) New Agents on the Horizon in Gastric Cancer. Annals of Oncology, 28, 1767-1775.
https://doi.org/10.1093/annonc/mdx051
|
[67]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[68]
|
Dolan, D.E. and Gupta, S. (2014) PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control, 21, 231-237.
https://doi.org/10.1177/107327481402100308
|
[69]
|
Li, Y., Liu, S., Hernandez, J., Vence, L., Hwu, P. and Radvanyi, L. (2010) MART-1-Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation in Vitro. The Journal of Immunology, 184, 452-465.
https://doi.org/10.4049/jimmunol.0901101
|
[70]
|
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., et al. (2011) Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy. Seminars in Oncology, 37, 533-546.
https://doi.org/10.1053/j.seminoncol.2010.09.015
|
[71]
|
Dudley, M.E., Wunderlich, J.R., Shelton, T.E., Even, J. and Rosenberg, S.A. (2003) Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients. Journal of Immunotherapy, 26, 332-342.
https://doi.org/10.1097/00002371-200307000-00005
|
[72]
|
Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., et al. (2005) Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma. Journal of Clinical Oncology, 23, 2346-2357.
https://doi.org/10.1200/JCO.2005.00.240
|
[73]
|
Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., et al. (2002) Cancer Regression and Autoimmunity in Patients after Clonal Repopulation with Antitumor Lymphocytes. Science, 298, 850-854.
https://doi.org/10.1126/science.1076514
|
[74]
|
Besser, M.J., Shapira-Frommer, R., Treves, A.J., Zippel, D., Itzhaki, O., Hershkovitz, L., et al. (2010) Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 16, 2646-2655.
https://doi.org/10.1158/1078-0432.CCR-10-0041
|
[75]
|
Besser, M.J., Shapira-Frommer, R., Itzhaki, O., Treves, A.J., Zippel, D.B., Levy, D., et al. (2013) Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clinical Cancer Research, 19, 4792-4800.
https://doi.org/10.1158/1078-0432.CCR-13-0380
|
[76]
|
Radvanyi, L.G., Bernatchez, C., Zhang, M., Fox, P.S., Miller, P., Chacon, J., et al. (2012) Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 18, 6758-6770.
https://doi.org/10.1158/1078-0432.CCR-12-1177
|
[77]
|
Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., et al. (2012) Efficacy of Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes after Lymphopenia Induction for Metastatic Melanoma. Journal of Immunotherapy, 35, 615-620. https://doi.org/10.1097/CJI.0b013e31826e8f5f
|
[78]
|
Aoki, Y., Takakuwa, K., Kodama, S., Tanaka, K., Takahashi, M., Tokunaga, A., et al. (1991) Use of Adoptive Transfer of Tumor-Infiltrating Lymphocytes Alone or in Combination with Cisplatin-Containing Chemotherapy in Patients with Epithelial Ovarian Cancer. Cancer Research, 51, 1934-1939.
|
[79]
|
Rosenberg, S.A., Spiess, P. and Lafreniere, R. (1986) A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science, 233, 1318-1321. https://doi.org/10.1126/science.3489291
|
[80]
|
Berenson, J., Einstein, A. and Fefer, A. (1975) Syngeneic Adoptive Immunotherapy and Chemoimmuno-Therapy of a Friend Leukemia: Requirement for T Cells. The Journal of Immunology, 115, 234-238.
|
[81]
|
Cameron, R.B., Spiess, P.J. and Rosenberg, S.A. (1990) Synergistic Antitumor Activity of Tumor-Infiltrating Lymphocytes, Interleukin-2, and Local Tumor Irradiation. Journal of Experimental Medicine, 171, 249-263.
https://doi.org/10.1084/jem.171.1.249
|
[82]
|
North, R. (1982) Cyclophosphamide-Facilitated Adoptive Immunotherapy of an Established Tumor Depends on Elimination of Tumor-Induced Suppressor T Cells. Journal of Experimental Medicine, 55, 1063-1074.
https://doi.org/10.1084/jem.155.4.1063
|
[83]
|
Rosenberg, A.S., Packard, S.B. and Abersold, M.P. (1988) Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma—A Preliminary Report. The New England Journal of Medicine, 319, 1676-1680. https://doi.org/10.1056/NEJM198812223192527
|
[84]
|
Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., et al. (2008) Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology, 26, 5233-5239. https://doi.org/10.1200/JCO.2008.16.5449
|
[85]
|
Linnemann, C., et al. (2015) High-Throughput Epitope Discovery Reveals Frequent Recognition of Neo-Antigens by CD4+ T Cells in Human Melanoma. Nature Medicine, 21, 81-85. https://doi.org/10.1038/nm.3773
|
[86]
|
Rajasagi, M., et al. (2014) Systematic Identification of Personal Tumor-Specific Neoantigens in Chronic Lymphocytic Leukemia. Blood, 124, 453-462.
https://doi.org/10.1182/blood-2014-04-567933
|
[87]
|
Rizvi, N.A., et al. (2015) Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128.
https://doi.org/10.1126/science.aaa1348
|
[88]
|
Tran, E., et al. (2014) Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science, 344, 641-645.
https://doi.org/10.1126/science.1251102
|
[89]
|
Tran, E., Ahmadzadeh, M., Lu, Y.C., et al. (2015) Immunogenicity of Somatic Mutations in Human Gastrointestinal Cancers. Science, 350, 1387-1390.
https://doi.org/10.1126/science.aad1253
|
[90]
|
Rosenberg, S.A., Goff, S.L., Feldman, S.A., Zacharakis, N., et al. (2018) Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer. Nature Medicine, 24, 724-730.
https://doi.org/10.1038/s41591-018-0040-8
|
[91]
|
Sewell, A.K., Crowther, M.D., Dolton, G., Legut, M., et al. (2020) Genome-Wide CRISPR-Cas9 Screening Reveals Ubiquitous T Cell Cancer Targeting via the Monomorphic MHC Class I-Related Protein MR1. Nature Immunology, 21, 178-185.
https://doi.org/10.1038/s41590-019-0578-8
|
[92]
|
Abd-El-Rheem, M.S.A. (1997) The Use of Moist Heat as Immuno Stimulant in Definitive Treatment of Cutaneous Cancer and Other Affections. The Alexandria Journal of Veterinary Sciences, 13, 533-538.
|